Close menu




October 12th, 2021 | 13:09 CEST

Infineon, BrainChip, Palantir - Spoiled for choice!

  • Technology
Photo credits: pixabay.com

The chip shortage is having an increasingly negative impact on supply chains. In Mecklenburg-Vorpommern, short-time work has now been declared at some suppliers to the automotive industry. First, the pandemic and the associated uncertainties among consumers caused less demand. Now, demand is suddenly back, but it cannot be satisfied because the supply chains from Asia are not yet functioning properly. Market observers expect these constraints to continue into next year. The chip crisis has now existed since the Evergreen disaster in the Suez Canal and seems to be with us for longer. We take a look at some tech stocks in the near vicinity.

time to read: 4 minutes | Author: André Will-Laudien
ISIN: INFINEON TECH.AG NA O.N. | DE0006231004 , BRAINCHIP HOLDINGS LTD | AU000000BRN8 , PALANTIR TECHNOLOGIES INC | US69608A1088

Table of contents:


    Infineon - Sell-off at lofty heights

    Infineon shares recently lost almost 10% from the annual high of around EUR 38.5. The reason was a press conference that offered an outlook on expectations for the next fiscal year. "The year 2022 will be a strong year," stated CEO Reinhard Ploss. The Group is currently benefiting strongly from the booming demand for chips. The trends around electrification and digitalization, for example, in the automotive sector, ensure full order books. CO2 reduction and the desire to make things intelligent and securely networked are the important underlying trends in all technology-oriented industries.

    As a result, sales in the new fiscal year 2021/22 are expected to increase in the mid-teens percentage range, as the Group announced at the last Investor Day. The operating margin in the segment result is also expected to increase to around 20%. However, Infineon expects significantly higher investments of EUR 2.4 billion. The medium-term growth targets were thus confirmed, but the capital market had probably expected somewhat more. Despite positive analyst comments, the share price fell. The chart picture has thus deteriorated in the short term. Therefore, secure your investment with a stop at EUR 33.80, where there is significant medium-term support.

    BrainChip Holdings - Innovations for the future

    While traditional chips are subject to an extreme supply shortage, powerful innovations are already being designed in the development departments. That is because progress is moving forward in leaps and bounds. Autonomous driving, facial and voice recognition, service bots and cloud security are the buzzwords. In sum, that is a lot of applications for the use of artificial intelligence (AI).

    BrainChip Holdings is an Australian semiconductor company that manufactures a revolutionary neuromorphic processor called "Akida." This chip is the first fully digital computer chip that functions in the same way as the human brain, i.e. it processes so-called spikes instead of traditional computer data.

    The Akida processor is economical because it generates hardly any heat and requires only milliwatts to operate. That means that it is used precisely where CO2 has to be saved and where there are corresponding restrictions due to the construction. It does not transmit any data to the outside world and can only be accessed using highly secure tools, making it a top-level solution for data protection. Since Akida does most of its processing on the chip and not in data centers, it does not require a constant Internet connection. It thus takes so-called edge computing to a whole new level.

    Prominent customers include organizations such as NASA, Valeo, NaNose Medical, Renesas and Ford. With this list of customers, BrainChip already covers several industries with its technology. Strong growth is likely to be seen in cloud and edge computing using AI in the coming years. Renesas is a major supplier to the automotive industry in the area of chips. Self-thinking vehicles will be particularly interesting here in the future. It is a megatrend, as they are even in development at Apple and Google.

    The BRN share is actively traded in Australia, on the Nasdaq and in Germany. Its market capitalization is currently around EUR 410 million. Profit-taking in the entire chip sector recently pushed the share price back down to EUR 0.26. In the medium term, however, the value is highly interesting. Get first-hand information about the Company from CFO Ken Scarince at the investor conference "IIF - International Investment Forum" on October 14.

    Palantir Technologies - Not quite getting off the ground

    Shares of Palantir Technologies have been in a tight sideways range for months now. The data specialist has closed many lucrative deals this year, including with the British government and the US military. However, the share has not benefited from the good news so far and is currently trending back towards the lower trend limit at around EUR 20. Here also lies important medium-term support.

    The NASDAQ has corrected by around 10% in the last few weeks, while Palantir has corrected by about 20%. Analytically, the Company is valued with a 2022 P/E of 24 and P/B of 120. Although this has somewhat reduced the astronomical valuation since January, when the stock weighed in at over EUR 50 billion, the title is still expensive today. With the share price continuing to move sideways, the stock can, of course, grow into its current valuation in 2-3 years. However, this is not good news for buyers.

    The next quarterly figures, which are expected to be published on November 11, could provide new buying impetus. It is estimated that sales will grow by 33% to around USD 385 million. If the figures miss the high expectations, things will get frosty.


    Many issues are moving the high-tech sector at the moment. These are raw material shortages, supply chain issues and increasing demand for energy-efficient products. Growth momentum remains very high in the tech sectors, but the stock market has already factored these factors into its valuations. If there are disappointments here, prices fall very quickly, as in the case of Infineon and Palantir, for example. The Australian BrainChip is still very young and can still process some sector dynamics positively.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    André Will-Laudien

    Born in Munich, he first studied economics and graduated in business administration at the Ludwig-Maximilians-University in 1995. As he was involved with the stock market at a very early stage, he now has more than 30 years of experience in the capital markets.

    About the author



    Related comments:

    Commented by Juliane Zielonka on September 30th, 2022 | 10:59 CEST

    Biogen, XPhyto, BioNTech: Alzheimer's disease, depression, cancer - Pharma for life

    • Biotechnology
    • Pharma
    • Investments
    • Technology

    About 350 million people worldwide are affected by depression, a disorder of the brain. Each person also has a 16 to 20% chance of becoming depressed. Reason enough for the Canadian Company XPhyto Therapeutics to research a drug that is not addictive and can defeat the mental health-related medical condition. This week, Biogen, among others, achieved a breakthrough with an active substance against Alzheimer's disease. And if you follow the Bundesliga closely, you may be aware of the cases of testicular cancer among the players. Now BioNTech senses a new opportunity...

    Read

    Commented by Fabian Lorenz on September 29th, 2022 | 13:17 CEST

    Up to 200% share price potential: Kion, BioNTech, Aspermont in analyst check

    • Technology
    • Biotechnology
    • Investments

    The profit warning was a shock for Kion shareholders. Accordingly, the share price halved to EUR 20 in September alone. Now analysts are also slashing their estimates. The price targets for the forklift manufacturer are falling accordingly. Berenberg surprises with a high price target for the BioNTech share. At the same time, the analysts emphasize their hope for a continued generous dividend. Shareholders could thus be kept in good spirits until the next blockbuster. The roadshow of Aspermont in Germany has probably also created a good mood. At least the share price has jumped. The current consolidation could be an entry opportunity. Analysts see a price potential of over 200%.

    Read

    Commented by Carsten Mainitz on September 29th, 2022 | 12:01 CEST

    Verbio, Kleos Space, KWS Saat - This news is moving share prices!

    • Space
    • Technology
    • Investments

    Increased uncertainties in geopolitics, rampant inflation with exploding commodity and energy prices, and higher interest rates are making it increasingly difficult for companies to meet the forecasts they issued at the beginning of the year. Recent examples include battery manufacturer Varta and real estate financier Hypoport, which had to withdraw their annual targets. In addition, however, a number of companies have been able to surprise on the upside despite all the challenges.

    Read